Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy : A patient series. / Lund, Tamara; Thomsen, Simon Francis.
I: Dermatologic Therapy, Bind 30, Nr. 3, e12454, 05.2017.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy
T2 - A patient series
AU - Lund, Tamara
AU - Thomsen, Simon Francis
PY - 2017/5
Y1 - 2017/5
N2 - From 2002 to 2016 a total of seven women with severe refractory psoriasis were exposed to the TNF-inhibitors infliximab and adalimumab or to the IL12/23 inhibitor ustekinumab during one or more pregnancies. Maternal, fetal or teratogenic toxicity were not detected during pregnancy and puerperium. All pregnancies were uneventful and resulted in delivery of 10 healthy children in total, one of the women is due February 2017. Postpartum, five of the women were lactating, but none of the women or newborns developed adverse reactions. Data on safety of treatment during breastfeeding are sparse, but so far appears to be safe due to the lack of absorption across the gastrointestinal lining. Currently biological therapy with either TNF-inhibitors or ustekinumab is not recommended during pregnancy, however in selected women with severe psoriasis these treatment modalities may be considered.
AB - From 2002 to 2016 a total of seven women with severe refractory psoriasis were exposed to the TNF-inhibitors infliximab and adalimumab or to the IL12/23 inhibitor ustekinumab during one or more pregnancies. Maternal, fetal or teratogenic toxicity were not detected during pregnancy and puerperium. All pregnancies were uneventful and resulted in delivery of 10 healthy children in total, one of the women is due February 2017. Postpartum, five of the women were lactating, but none of the women or newborns developed adverse reactions. Data on safety of treatment during breastfeeding are sparse, but so far appears to be safe due to the lack of absorption across the gastrointestinal lining. Currently biological therapy with either TNF-inhibitors or ustekinumab is not recommended during pregnancy, however in selected women with severe psoriasis these treatment modalities may be considered.
KW - biologics
KW - inflammatory disorders
KW - pharmacology
KW - psoriasis
KW - therapy-systemic
U2 - 10.1111/dth.12454
DO - 10.1111/dth.12454
M3 - Journal article
C2 - 28071837
AN - SCOPUS:85020073354
VL - 30
JO - Dermatologic Therapy
JF - Dermatologic Therapy
SN - 1396-0296
IS - 3
M1 - e12454
ER -
ID: 196441549